For the Inventor, By the Inventor

Enter assignee name

Ballerup, Denmark

Neurosearch A/s

USPTO Granted Patents = 206

% Expired Patents = 58.3

CIPO Patents = 12

EPO Patents = 40

Forward Citations = 869

Loading Chart...

Loading Chart...

125 inventors (with patents filed for the assignee):

Dan Peters (107 out of 115 patents)

Gunnar M Olsen (72 out of 72 patents)

Elsebet Østergaard Nielsen (59 out of 65 patents)

4. Lene Teuber (38 out of 44 patents)

5. Palle Christophersen (28 out of 41 patents)

6. Elsebet Ostergaard Nielsen (26 out of 27 patents)

7. Frank Watjen (26 out of 57 patents)

8. Philip K Ahring (23 out of 25 patents)

9. Peter Moldt (23 out of 24 patents)

10. Daniel B Timmermann (22 out of 25 patents)

11. John Paul Redrobe (19 out of 19 patents)

12. Simon Feldbaek Nielsen (16 out of 22 patents)

13. Birgitte Langer Eriksen (16 out of 22 patents)

14. Tino Dyhring Jørgensen (16 out of 16 patents)

15. Bjarne H Dahl (14 out of 14 patents)

Core Competencies:

Potassium Channel Modulators

Monoamine Neurotransmitter

Cholinergic Receptor

Pyrimidine Derivatives

Bicyclic Compounds

Diazabicyclic Aryl

Piperidine Derivatives

Acyclic Compounds

Neurotrophic Activity

Nicotinic Acetylcholine

206 patents: Sort by Forward Citations

1. 8415358 - Pyrazine derivatives and their use as potassium channel modulators (2013-04-09),

2. 8410271 - Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2013-04-02),

3. 8372832 - 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and their medical use (2013-02-12),

4. 8362024 - Purinyl derivatives and their use as potassium channel modulators (2013-01-29),

5. 8343960 - 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use (2013-01-01),

6. 8288418 - [object Object] (2012-10-16),

7. 8268838 - Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators (2012-09-18),

8. 8263617 - Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2012-09-11),

9. 8263611 - Hydrochloride salt of an azabicyclo[3.2.1]octane derivative (2012-09-11),

10. 8252806 - Potassium channel modulating agents and their medical use (2012-08-28),

11. 8236793 - Diazabicyclic aryl derivatives as cholinergic receptor modulators (2012-08-07),

12. 8222262 - Indazolyl derivatives useful as potassium channel modulating agents (2012-07-17),

13. 8202884 - Treatment of type 2 diabetes (2012-06-19),

14. 8178544 - 2, 3-diamino-quinazolinone derivatives and their medical use (2012-05-15),

15. 8173658 - Diazabicycylic aryl derivatives and their medical use (2012-05-08),

Company Overview

Neurosearch A/S, based in Ballerup, Denmark, specializes in neuropharmacology, focusing on the development of innovative therapies targeting neurological disorders. The company is engaged in the research and development of potassium channel modulators and compounds affecting monoamine neurotransmitters and cholinergic receptors. Their expertise extends to a variety of chemical classes, including pyrimidine derivatives and bicyclic compounds, positioning them at the forefront of neuropharmaceutical advancements.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

206 Patents

#3 in Ballerup

#22 in Denmark

#4,124 in the World

Ballerup, Denmark

Neurosearch A/s

Forward Citations = 869

125 inventors:

Dan Peters (107 out of 115 patents)

Gunnar M Olsen (72 out of 72 patents)

Elsebet Østergaard Nielsen (59 out of 65 patents)

4. Lene Teuber (38 out of 44 patents)

5. Palle Christophersen (28 out of 41 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Neurosearch A/s. Retrieved from https://idiyas.com/company/neurosearch-a-s

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…